Quanterix Shareholder Opposes Proposed Akoya Biosciences Merger

MT Newswires Live
03-11

Quanterix (QTRX) shareholder Kent Lake said Tuesday that it opposes the company's proposed deal with Akoya Biosciences (AKYA).

Kent Lake, which owns 7.25% of Quanterix's stock, argued the deal is bad for Quanterix shareholders as it values Akoya almost five times higher than Quanterix, despite Quanterix's "superior" growth and market opportunity.

Kent Lake said in its claims that Quanterix ended up bidding against itself for Akoya, as other potential buyers backed out. It also raised concerns about the Quanterix board, suggesting that some directors have conflicts of interest and have not acted in the best interests of shareholders.

Kent Lake urged Quanterix stockholders to vote against the proposed merger and also said it recently nominated three independent board candidates to represent shareholders' interests better.

Quanterix and Akoya Biosciences did not immediately reply to MT Newswires' request for comments.

QTRX shares were up 3.5% and AKYA shares were 5.2% higher in recent trading.

Price: 7.53, Change: +0.25, Percent Change: +3.43

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10